Tamoxifen treatment of bleeding irregularities associated with Norplant use

被引:21
作者
Abdel-Aleem, H [1 ]
Shaaban, OM [1 ]
Amin, AF [1 ]
Abdel-Aleem, AA [1 ]
机构
[1] Assiut Univ Hosp, Dept Obstet & Gynecol, Asssiut 71511, Egypt
关键词
contraception; progestogen-only; norplant; SERM; bleeding; tamoxifen;
D O I
10.1016/j.contraception.2005.05.015
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: To evaluate the possible role of tamoxifen (selective estrogen receptor modulators, SERM) in treating bleeding irregularities associated with Norplant contraceptive use. Material and Methods: Randomized clinical trial including 100 Norplant users complaining of vaginal bleeding irregularities. The trial was conducted in the Family Planning Clinic of Assiut University Hospital. Women were assigned at random to receive tamoxifen tablets (10 mg) twice daily for 10 days or similar placebo. Women were followed-up for 3 months. The end points were percentage of women who stopped bleeding during treatment, bleeding/spotting days during the period of follow-up, effect of treatment on their lifestyle, and side effects and discontinuation of contraception. Results: There was good compliance with treatment. At the end of treatment, a significantly higher percentage of tamoxifen users stopped bleeding in comparison to the control group (88% vs. 68%, respectively; p=.016). Women who used tamoxifen had significantly less bleeding and/or spotting days than women who used placebo, during the first and second months. During the third month, there were no significant differences between the two groups. Women who used tamoxifen reported improvement in performing household activities, religious duties and in sexual life, during the first 2 months. In the third month, there were no differences between the two groups. There were no significant differences between tamoxifen and placebo groups in reporting side effects. In the group who used tamoxifen, two women discontinued Norplant use because of bleeding vs. nine women in the placebo group. Conclusion: Tamoxifen use at a dose of 10 mg twice daily orally, for 10 days, has a beneficial effect on vaginal bleeding associated with Norplant use. In addition, the bleeding pattern was better in women who used tamoxifen for the following 2 months after treatment. However, these results have to be confirmed in a larger trial before advocating this line of treatment. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:432 / 437
页数:6
相关论文
共 28 条
[1]  
Acquadro C, 1996, QUALITY LIFE PHARMAC
[2]   Hormonal treatment for bleeding irregularities in Norplant implant users [J].
AlvarezSanchez, F ;
Brache, V ;
Thevenin, F ;
Cochon, L ;
Faundes, A .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (03) :919-922
[3]   Management of irregular uterine bleeding and spotting associated with Norplant(R) [J].
Archer, DF ;
Philput, CA ;
Weber, ME .
HUMAN REPRODUCTION, 1996, 11 :24-30
[4]   THE ASSOCIATION BETWEEN VAGINAL BLEEDING PATTERNS AND REASONS FOR DISCONTINUATION OF CONTRACEPTIVE USE [J].
BELSEY, EM .
CONTRACEPTION, 1988, 38 (02) :207-225
[5]   Tamoxifen therapy for breast cancer and endometrial cancer risk [J].
Bernstein, L ;
Deapen, D ;
Cerhan, JR ;
Schwartz, SM ;
Liff, J ;
McGann-Maloney, E ;
Perlman, JA ;
Ford, L .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) :1654-1662
[6]   Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies [J].
Cohen, I ;
Beyth, Y ;
Altaras, MM ;
Shapira, J ;
Tepper, R ;
Cardoba, M ;
Yigael, D ;
Figer, A ;
Fishman, A ;
Berenhein, J .
GYNECOLOGIC ONCOLOGY, 1997, 67 (01) :8-15
[7]   Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding [J].
d'Arcangues, C ;
Piaggio, G ;
Brache, V ;
Aissa, RB ;
Hazelden, C ;
Massai, R ;
Pinol, A ;
Subakir, SB ;
Su-juan, G .
CONTRACEPTION, 2004, 70 (06) :451-462
[8]  
DIAZ S, 1990, CONTRACEPTION, V42, P97
[9]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[10]  
GAGLIARDI A, 1993, CANCER RES, V53, P533